-+ 0.00%
-+ 0.00%
-+ 0.00%

Health Canada Accepts Semaglutide 2.4 mg As Supplemental New Drug Submission Under Priority Review Policy

Benzinga·05/02/2025 13:22:43
Listen to the news
  • It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%.1 
  • Left untreated, MASH can progress to serious and even fatal outcomes, such as cirrhosis, liver cancer, and the need for liver transplant.2